The latest price target for Celldex Therapeutics (NASDAQ:CLDX) was reported by Cantor Fitzgerald on September 18, 2024. The analyst firm set a price target for $67.00 expecting CLDX to rise to within 12 months (a possible 60.10% upside). 22 analyst firms have reported ratings in the last year.

The latest analyst rating for Celldex Therapeutics (NASDAQ:CLDX) was provided by Cantor Fitzgerald, and Celldex Therapeutics reiterated their overweight rating.

The last upgrade for Celldex Therapeutics Inc happened on November 10, 2023 when Wells Fargo raised their price target to $27. Wells Fargo previously had an underweight for Celldex Therapeutics Inc.

There is no last downgrade for Celldex Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Celldex Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Celldex Therapeutics was filed on September 18, 2024 so you should expect the next rating to be made available sometime around September 18, 2025.

While ratings are subjective and will change, the latest Celldex Therapeutics (CLDX) rating was a reiterated with a price target of $67.00 to $67.00. The current price Celldex Therapeutics (CLDX) is trading at is $41.85, which is out of the analyst’s predicted range.